Eli Lilly’s Anticipated Weight Loss Drug Helped People Lose 56 Pounds On Average
Eli Lilly's weight-loss drug retatrutide shows significant efficacy in new clinical trials, prompting plans for a 2027 FDA filing.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Eli Lilly has announced positive results from two additional Phase 3 clinical trials for its obesity drug, retatrutide. The drug, a triple agonist, demonstrated improvements in both weight loss and A1C levels, with participants losing an average of 56 pounds.
Coverage from Barron’s, Yahoo Finance, FirstWord Pharma, PR Newswire, BioPharma Dive, and Forbes highlights the company's timeline for submitting the drug for regulatory approval. Reports note that Lilly shares rose following the release of the trial data.
Coverage does not yet specify the exact date for the submission or potential commercial release timelines beyond that year.
Synthesized by headlinez.news from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (83% supported) Updated 46m ago.
Quick answers
What drug is being tested by Eli Lilly?
The company is testing a triple agonist weight-loss drug called retatrutide.
When does the company plan to seek FDA approval?
Eli Lilly plans to file for FDA approval in early 2027.
What were the results of the recent Phase 3 trials?
Participants experienced improvements in A1C levels and an average weight loss of 56 pounds.
Coverage (6)
- Lilly Stock Rises. It Plans to Seek Approval for Newest Weight-Loss Drug in 2027 Barron's · 1d ago
- Eli Lilly's Retatrutide Clears Two More Trials Ahead of 2027 Filing Yahoo Finance · 1d ago
- Latest obesity TRIUMPH for Lilly's retatrutide sets up FDA filing for early next year FirstWord Pharma · 1d ago
- Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C PR Newswire · 1d ago
- Lilly, with new data, to seek FDA approval of obesity drug retatrutide BioPharma Dive · 1d ago
- Eli Lilly’s Anticipated Weight Loss Drug Helped People Lose 56 Pounds On Average Forbes · 1d ago
Topics
Related trends
Trump's former top food official: Cyclospora outbreak ‘approaching catastrophic’ level
Industry groups and former officials are raising alarms over a growing Cyclospora outbreak, pushing for immediate federal oversight and improved traceability.
US FDA approves over-the-counter Tylenol combination pill for pain relief
The FDA has granted approval for the first over-the-counter fixed-dose combination of acetaminophen and naproxen sodium.
This Billionaire Made $360 Million Selling His Psychedelic Company To Eli Lilly
Eli Lilly's $3.8 billion acquisition of a psychedelic company draws industry attention to the firm’s renewed focus on neuropsychiatry and Alzheimer's prevention.
Confusing product recall adds to US cyclospora outbreak uncertainty
A spreading cyclosporiasis outbreak has prompted a major supply chain shift at Taylor Farms as food businesses navigate declining consumer confidence.
CDC expands largest known U.S. cyclospora outbreak to 9 states
The CDC has expanded its investigation into a multi-state cyclospora outbreak linked to iceberg lettuce and Taco Bell locations.
An FDA Panel Just Endorsed These Unproven Peptides
An FDA advisory panel has voted to authorize certain peptides for use, diverging from the recommendations of agency scientists.